The primary purpose of this study is to determine the effect of repeated administration of itraconazole on the pharmacokinetic (PK) profile of S-309309; and the PK of S-309309 following administration of S-309309 alone and co-administration with itraconazole
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
14
Administered as oral capsules
Administered as oral capsules
Fortrea Clinical Research Unit Inc.
Dallas, Texas, United States
Area Under the Concentration-Time Curve Extrapolated From Time 0 to Infinity (AUC0-inf) After Administration of S-309309
Time frame: Up to 2 weeks postdose on Days 1, 19
Area Under the Concentration-Time Curve Extrapolated From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) After Administration of S-309309
Time frame: Up to 2 weeks postdose on Days 1, 19
Maximum Observed Plasma Concentration (Cmax) After Administration of S-309309
Time frame: Up to 2 weeks postdose on Days 1, 19
Number of Participants With Adverse Events (AEs)
Time frame: Up to 5 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.